AstraZeneca bags another cancer drug deal, this time with Inovio

LONDON, Aug 10 (Reuters) - AstraZeneca has clinched its third deal in less than a week to bolster its strategically important cancer drug pipeline by signing up rights to an experimental immune system-boosting medicine from Inovio Pharmaceuticals.